Theranostics, An Issue of PET Clinics
- 1st Edition, Volume 16-3 - June 7, 2021
- Editors: Ali Gholamrezanezhad, Hojjat Ahmadzadehfar
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 1 3 0 7 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 1 3 0 8 - 2
This issue of PET Clinics focuses on Theranostics and is edited by Drs. Ali Gholamrezanezhad and Hojjat Ahmadzadehfar. Articles will include: Good Clinical Practice for… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis issue of PET Clinics focuses on Theranostics and is edited by Drs. Ali Gholamrezanezhad and Hojjat Ahmadzadehfar. Articles will include: Good Clinical Practice for Theranostics; Theranostics in Neuroendocrine Tumors; Neuroendocrine Tumors: Imaging Perspective; Prostate Cancer Theranostics: From Target Description to Imaging; Prostate Cancer Theranostics: PSMA-targeted Therapy; Theranostics in Brain Tumors; Theranostics in Neuroblastoma; Theranostics in Thyroid Cancer; and more!
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- CME Accreditation Page
- General Concepts in Theranostics
- Key points
- Introduction
- Discussion
- Controversies
- Perspectives
- Summary
- Clinics care points
- An Impressive Approach in Nuclear Medicine: Theranostics
- Key points
- Introduction
- Treatment of hyperparathyroidism and thyroid cancer in nuclear medicine
- Treatment of neuroendocrine tumor in nuclear medicine
- Treatment of prostate cancer in nuclear medicine
- Treatment of bone metastases in nuclear medicine
- Theranostics applications in neuroblastoma
- Treatment of melanoma in nuclear medicine
- Theranostics applications in multiple myeloma
- A new horizon for tumor targeting and therapy: fibroblast activation protein inhibitor
- Summary
- The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging
- Key points
- Introduction
- Tumor stroma
- Fibroblast activation protein ligands in PET imaging
- Summary
- Clinics care points
- Neuroendocrine Tumors: Imaging Perspective
- Key points
- Introduction
- Role of PET imaging to identify patients with somatostatin receptor positivity
- joint 18F-fluorodeoxyglucose and 68Ga-DOTA-peptide PET/computed tomography use in the evaluation of neuroendocrine tumor
- Outstanding questions in imaging of neuroendocrine tumors for peptide radionuclide receptor therapy planning
- Imaging to quantify dose
- Can dose absorbed be predicted based on functional imaging?
- The principles of individualized dosimetry
- Variability and standardization of individualized dosimetry
- Ensuring consistency of dose estimates across centers through quality assurance
- From absorbed dose to biological effective dose
- Imaging to predict outcomes
- Summary
- Disclosures
- Clinics care points
- Theragnostics in Neuroendocrine Tumors
- Key points
- Introduction
- Clinical care points
- Discussion
- Summary
- Theranostics in Thyroid Cancer
- Key points
- Introduction
- Sodium-iodine symporter
- Radioiodine therapy in differentiated thyroid cancer
- Radioiodine imaging with 131I
- Radioiodine-refractory differentiated thyroid cancer
- Redifferentiation therapy
- Further possibilities of theranostics in thyroid cancer
- Summary
- Clinics care points
- Prostate Cancer Theranostics: From Target Description to Imaging
- Key points
- Introduction
- Prostate-specific membrane antigen
- Prostate-specific membrane antigen-based imaging and theranostics
- Factors influencing prostate-specific membrane antigen expression
- The prostate-specific membrane antigen radioligands
- Theranostic imaging
- Controversies in PSMA imaging
- Summary
- Clinics care points
- Prostate Cancer Theranostics: PSMA Targeted Therapy
- Key points
- Introduction
- Imaging and therapy
- Future directions
- Disclosures
- Theranostics in Brain Tumors
- Key points
- Introduction
- Biological targets for targeted therapy
- Routes of drug delivery to brain tumors
- PET-based precision imaging and current challenges of theranostics in neuro-oncology
- Target expression assessment and tumor heterogeneity
- Pharmacokinetic assessment and biodistribution
- Evaluation of pharmacodynamics and cancer biology monitoring
- Future directions
- Summary
- Conflict of interest
- Financial disclosures
- Clinics care points
- Theranostics in Neuroblastoma
- Key points
- Introduction
- Discussion
- Summary
- Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders
- Key points
- Introduction
- Theranostic approaches in the management of infections
- Theranostic approaches for cardiovascular diseases
- Theranostics approaches for rheumatic disease
- Future directions
- Summary
- Clinics care points
- Theranostic Agents in Musculoskeletal Disorders
- Key points
- Rheumatoid arthritis
- Osteoarthrosis
- Multiple myeloma
- Sarcoma
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 16-3
- Published: June 7, 2021
- Imprint: Elsevier
- Hardback ISBN: 9780323813075
- eBook ISBN: 9780323813082
AG
Ali Gholamrezanezhad
Affiliations and expertise
Keck School of Medicine, University of Southern California (USC) Los Angeles, California